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Abstract
Background: To improve efficiency in high throughput protein structure determination, we have
developed a database software package, Gene Composer, which facilitates the information-rich
design of protein constructs and their codon engineered synthetic gene sequences. With its
modular workflow design and numerous graphical user interfaces, Gene Composer enables
researchers to perform all common bio-informatics steps used in modern structure guided protein
engineering and synthetic gene engineering.
Results: An interactive Alignment Viewer allows the researcher to simultaneously visualize
sequence conservation in the context of known protein secondary structure, ligand contacts, water
contacts, crystal contacts, B-factors, solvent accessible area, residue property type and several other
useful property views. The Construct Design Module enables the facile design of novel protein
constructs with altered N- and C-termini, internal insertions or deletions, point mutations, and desired
affinitytags.The modifications can becombinedand permutedinto multipleproteinconstructs,andthen
virtually cloned in silico into defined expression vectors. The Gene Design Module uses a protein-to-
gene algorithm that automates the back-translation of a protein amino acid sequence into a codon
engineered nucleic acid gene sequence according to a selected codon usage table with minimal codon
usage threshold, defined G:C% content, and desired sequence features achieved through synonymous
codon selectionthat isoptimized for theintendedexpression system. The gene-to-oligo algorithm ofthe
Gene Design Module plans out all of the required overlapping oligonucleotides and mutagenic primers
needed to synthesize the desired gene constructs by PCR, and for physically cloning them into selected
vectors by the most popular subcloning strategies.
Conclusion: We present a complete description of Gene Composer functionality, and an efficient
PCR-basedsyntheticgeneassemblyprocedurewithmis-matchspecificendonucleaseerrorcorrectionin
combination with PIPEcloning. Ina sistermanuscript we presentdata onhow GeneComposerdesigned
genes and protein constructs can result in improved protein production for structural studies.
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Large-scale projects in genomic sequencing and protein
structure determination are producing enormous quan-
tities of data on the relationships between 2D gene
sequence and 3D protein structure. Moreover, such
efforts are providing experimental data on success factors
at every step in the gene to structure research endeavor.
Ideally, this wealth of information should be used in a
feedback cycle to facilitate the design and production of
genes and protein constructs that are optimized for the
successful production of functional protein samples for
structural studies. Fundamentally, this goal represents a
bioinformatics software challenge. With the goal of
improving yield and success rates of heterologous
protein production for structural studies, we have
developed Gene Composer, a database software package
which facilitates the information-rich design of protein
constructs and their codon engineered synthetic gene
sequences.
The redundancy of the genetic code allows any given
protein to be encoded by a very large number of possible
synonymous gene sequences. On average, each amino
acid can be encoded by approximately three different
codons (61 amino acid codons/20 amino acids). For a
t y p i c a l1 0 0a m i n oa c i dp r o t e i nt h e r ew o u l db e3
100 (~5 ×
10
47) different possible coding sequences. The degen-
eracy of the genetic code therefore allows the pressures of
natural selection to simultaneously influence both DNA
and RNA sequence features in addition to protein coding
function. DNA sequence elements and folded RNA
structures are known to play significant roles in gene
expression. As such, the overlapping information con-
tained in a gene sequence can be significantly more
complex than coding for a linear amino acid sequence.
For example in the tryptophan operon of E. coli,t h e
m R N Ac a nf o l di n t oo n eo ft w om u t u a l l ye x c l u s i v e
conformations that are a direct consequence of trypto-
phan availability [1]. These alternate conformations
affect mRNA stability and therefore alter the expression
of the encoded proteins. It is also well established that
codon preferences between species, and often between
gene families within a given species, can vary [2,3].
Therefore, some gene sequences may behave better than
others in supporting high-level translation for hetero-
logous protein expression. Being able to tailor synthetic
gene sequences by codon engineering to favor optimal
heterologous expression is a well established strategy for
improving heterologous protein expression for structural
biology [4].
Given the overlapping nature of information content in
gene sequences (DNA, RNA, and protein level) we
endeavored to create a database and software tool called
Gene Composer which facilitates the design of protein
constructs, guided by 2D and 3D information, while the
corresponding nucleic acid sequences are engineered for
both codon usage and other desired sequence features.
Gene Composer also enables the virtual cloning of the
designed gene constructs which, depending on user
preferences, can be parsed into data files for online
ordering of complete genes or overlapping oligonucleo-
tides that can be used for PCR-based gene assembly in
any standard molecular biology lab. Gene Composer
operates within the Windows® operating system and
utilizes a network based SQL server or Access® database
that is populated by users as they design genes. This
arrangement makes it possible for multiple users to go
back after time to design new construct variants that
improve on existing designs by inclusion of new
sequence or structural information from international
genome sequencing and structural genomics efforts. In
this report we describe how the synthetic gene design
modules of Gene Composer facilitate protein construct
engineering for structural studies, codon engineering for
heterologous protein production, and oligonucleotide
planning for PCR-based gene assembly with mismatch
endonuclease error correction.
Implementation and results
Gene Composer™ Software
Gene Composer has a modular design to facilitate the
work of protein engineers and structural biologists. It
combines, within a single database software product, the
ability to carry out comparative sequence alignments
(Alignment Viewer) that facilitates interactive protein
construct design with virtual cloning (Construct Design
Module), followed by codon engineering of novel
synthetic gene sequences that are optimized for protein
expression in various recombinant systems (Gene Design
Module). Gene Composer is written in C
++ for Windows®
operating systems, and runs together with either an
Access® or SQL® database.
Alignment Viewer
A typical gene design cycle is initiated when a user
defines a protein "target name" and a "project name"
which establishes key database identifiers for which all
subsequent Gene Composer workflow is associated.
Once these identifiers have been established, the user
is presented with a file navigation interface that allows
one to import information into the Gene Composer
database from multiple sources such as FASTA sequence
files from BLAST [5] searches, existing sequence align-
ments, simple text (.txt) files, and structure files from the
Protein Data Bank (PDB, http://www.rcsb.org/pdb).
From this imported information, Gene Composer uses
the popular ClustalW algorithm [6,7] to calculate
comparative protein sequence alignments, which are
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Alignment Viewer (Figure 1). This Alignment Viewer
allows the researcher to simultaneously visualize
sequence conservation in the context of known protein
secondary structure, ligand contacts, water contacts,
crystal contacts, residue property type and several other
useful property views that are used to guide interactive
decision making for protein construct design.
Areas of sequence conservation are highlighted within
the Alignment Viewer according to a user defined color
scheme and a consensus sequence is displayed below the
alignment. Protein secondary structure information is
extracted from PDB files and displayed in common
graphic annotation underneath their associated linear
amino acid sequences. Importantly, the Alignment
Viewer presents both the "chain" sequence for the
protein that went into crystallization as well as the
experimentally refined "model" sequence from the PDB
coordinate file. This allows the user to easily visualize
which amino acid residues had no structural information
reported in the PDB file, displayed as blank gaps in the
"model" sequence. Such residues are usually located
within highly flexible regions of the protein and do not
contribute to X-ray diffraction.
Users can define a threshold contact distance setting
(default setting is 3.4 Angstroms) which Gene Composer
uses to generate a simple distance matrix between non-
bonded, non-hydrogen atom centers in PDB files. The
resulting matrix is used to flag residues in the protein
model that participate in ligand contacts, water contacts,
and/or crystal contacts. Each contact type is annotated
within the Alignment Viewer with special visual symbols
displayed below the residue of interest (Figure 1). Crystal
contacts are indicated when non-hydrogen atoms of a
residue are positioned within 4.0 Angstroms of neigh-
boring molecule related by crystallographic or non-
crystallographic symmetry. Gene Composer has a data-
base of all protein crystal space groups required for the
crystal contact calculation. The ability to visualize
residues involved in crystal contacts helps the user to
identify residues that could be mutated to improve
crystal growth [8]. Gene Composer also calculates from
PDB file information the relative solvent accessible
Connolly surface area [9] and thermal B-factors for
residues which are displayed with relative color inten-
sities to provide a visual representation of the surface
location and mobility of amino acids. This facilitates the
visual identification of surface residues that are candi-
dates for surface entropy reduction mutagenesis which is
a commonly used to aid protein crystallization [10]. The
alignments can also be easily modified and annotated
with the aid of an interactive cursor that allows the user
to insert or delete sequences, residues, or spaces.
Importantly, the native amino acid residue numbering
scheme is preserved throughout any alignment manip-
ulations. However, since the amino acid sequence
numbering scheme of PDB files is often not necessarily
congruent with the residue numbering of native full
length gene sequences, users can select a given sequence
and re-define the starting residue number. In this way,
users can arrive at a common residue numbering scheme
to help ensure accuracy in subsequent construct design.
Finally, the information rich alignments can be saved in
the Gene Composer database and exported to several
other formats including *.aln, *.xml, and *.pdf for facile
data sharing between researchers.
Protein Construct Design and Automated Cloning
The Construct Design Module works in concert with the
Alignment Viewer allowing the researcher to interactively
define novel protein constructs with altered amino- and
carboxy-termini, internal insertions or deletions, point
mutations, and added affinity tags. The construct design
tools are connected to the Alignment Viewer by a cursor
that shows the user exactly where in the sequence
alignment the desired changes are being made. For
example, the user can set the cursor within the
Alignment Viewer at a domain boundary as visualized
in the comparative sequence alignment and then
truncate the construct at that site. The desired modifica-
tions can be virtually combined and permuted in silico to
arrive at multiple desired protein constructs (Figure 2).
The user can also add a variety of adaptor assemblies at
the DNA sequence level to facilitate the virtual and
physical cloning of the constructs into multiple defined
expression vectors (Figure 3). Importantly, the Gene
Composer virtual in silico cloning utility manages the
inserts, vectors, and adaptor assemblies as three inde-
pendent informatics components that are combined by
the user to arrive at final vector clones [11]. After the
virtual cloning is completed, the user can inspect the
entire vector with its adaptor assemblies and protein
construct inserts. In this way, the user can see exactly
how open reading frames are constructed and then easily
fix any virtual cloning errors before wet lab work is
performed. Many expression vectors come with their
own N-terminal or C-terminal affinity tags that must be
accurately fused in frame with the protein construct.
Visual inspection of the virtual clone ensures that the
open reading frame formed by the vector/adaptor/insert
combination is intact and accurate.
In order to automate the physical cloning of designed
constructs using either the Tecan Freedom Evo2 liquid
handling system http://www.tecan.com or handheld
pipettors, the Construct Design Module can automati-
cally plan out all of the required amplimers (primers)
BMC Biotechnology 2009, 9:36 http://www.biomedcentral.com/1472-6750/9/36
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Gene Composer software, Alignment View. Comparative sequence alignments and corresponding structural
information are organized by the Alignment Viewer of Gene Composer, shown here with PDB file sequences for human renal
dipeptidase (1ITU), and the amino acid sequences of full length human renal dipeptidase plus selected vertebrate homologues
(FASTA files read from a BLAST search using the amino acid sequence file of PDB file 1ITU). The sequence alignments are
produced by the popular ClustalW algorithm [6,7]. The conserved consensus sequence is also shown. Solvent accessible
surface area is represented in purple shading levels (light is low and dark is high) calculated according to Connolly [9]. Thermal
B-factors from the PDB file are normalized and represented in red shading levels (light is low and dark is high). Residues that
contain atoms within 3.5 Angstroms (or other user defined setting) of an oxygen atom of water molecules are illustrated with
a blue dot. Residues that contain atoms within 4.0 Angstrom (or other user defined setting) of a non-hydrogen atom of a small
molecule ligand are illustrated with colored circles or dots (excluding blue dots for water contacts). Residues that contain non-
hydrogen atoms within 4.0 Angstroms (or other user defined setting) of any non-hydrogen atom in a neighboring protein chain
are illustrated with a green diamond when space group symmetry operators are applied to build crystallographic neighbor
molecules, or a red diamond when the contact is between non-crystallographic symmetrically related polypeptide chains.
Protein secondary structural regions are represented by red helices for alpha helical regions, blue arrows for beta-sheet
regions, and green squiggles for turns, as defined the respective PDB file format.
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(page number not for citation purposes)and mutagenic oligonucleotides needed to produce the
gene constructs of interest by PCR from a defined
template. The template sequence can either be a native
cDNA sequence or a codon engineered synthetic DNA
sequence crafted by the Gene Design Module of Gene
Composer. The software creates a spreadsheet list of the
required oligonucleotides with defined quantity and
location within a bar coded 96 well plate that conforms
Figure 2
Gene Composer software, Protein Construct Design. The Construct Design tool of Gene Composer is a separate
window positioned below the Alignment Viewer. To start a Construct Design session, the user defines a Base Construct from
the Alignment Viewer (human protein sequence with black highlighted box), whose sequence is presented schematically (green
bar) with a sliding window (green box) that delimits the amino acid sequence of the portion of the Base Construct within the
sliding window (sequence above the green bar). The Alignment Viewer and Construct Design Tool are coordinated to move
with each other as the user conducts various construct design operations across the Base Construct. Desired truncation end
points are set by placing the cursor (red line in alignment) at desired sequence positions and inserting a right or left pointer for
N-terminal and C-terminal truncations, respectively. The user may also create mutations within the amino acid sequence
either as a single amino acid change (empty square), insertions (filled triangle above the inserted amino acids), deletions (filled,
inverted triangle), or a mutation pool defining multiple mutations at a single site (dotted line above the desired changes). Once
the desired construct modifications have been defined, the user can combine and permute any desired set of truncations and
mutations to generate virtual constructs shown in the lower Construct Design window. Each construct is given a unique
Construct ID and Construct Name according to a standardized schema that describes the N- and C-terminal residue numbers
and other features.
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(page number not for citation purposes)to Society of Biomolecular Screening (SBS) standards.
The spreadsheet is sent directly to oligonucleotide
vendors (e.g. IDT, Inc., Coralville, IA) who will typically
prepare and ship the oligo-plates within a week. Once
SBS plates containing the amplimers (terminal primers)
and mutagenic oligonucleotides have been obtained,
t h e yc a nt h e nb ep l a c e do nt h ed e c ko ft h eT e c a nl i q u i d
handler together with plates containing template DNA
(either cDNA or synthetic DNA), vector DNA, buffer
mixes, polymerase, and other enzymes at defined
Figure 3
Gene Composer software, Vector construct assembly viewer. Virtual construction of expression vectors with
designed gene inserts is accomplished through the Vector Construct Assembly Viewer shown here. All vectors, adaptor
assemblies, and engineered gene constructs are stored in the Gene Composer database. Virtual cloning starts with the
selection of all gene constructs that are to be cloned (upper left, Construct window). The user then selects a desired plasmid
expression vector (pBACgus displayed as black circular arrow). Based on data associated with the expression vector, the Gene
Composer software is cognizant of the intended point of insertion for the protein open reading frame (green arc). The
sequence details are shown with a radial sequence viewer (blue wedge), which displays the nucleic acid sequence in that region
(window with blue arrows). User defined adaptor assemblies (Adaptor Assembly window, lower left) are used to combine the
selected expression vector with desired gene construct inserts (orange line). The user arranges the adapters in the order
desired, selects a vector from the pull-down menu and the software assembles the elements into a final construct. In the
example shown, there is a BamHI restriction site (blue square) at the 5' end of the insert, while the 3' end contains an in frame
hexa-histidine (His6) amino acid affinity tag sequence (orange square), a double translation terminator (black square), and a
HindIII restriction site (green square). The amino acid sequence of the construct plus added tags is also displayed.
BMC Biotechnology 2009, 9:36 http://www.biomedcentral.com/1472-6750/9/36
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(page number not for citation purposes)locations. With this information, the Construct Design
Module can compute a script of pipetting instructions for
the Tecan liquid handler to perform all the necessary
liquid handling events needed to pool template DNA
with amplimers, polymerase, and buffers within indivi-
dual wells of a 96-well PCR plate. Alternatively, the same
script of pipetting, PCR, and cloning events can be
executed manually by a researcher with a handheld
pipettor. After the PCR plates are filled with the necessary
reagents, either the user or the robotic arm of the Tecan
robot places them onto thermal cycler which carries out
the necessary PCR reactions to produce "adapted"
inserts. In the case where point mutations, deletions, or
insertions are required at a single site within the insert
sequence, the Tecan platform (or the researcher with a
hand held pipette) is scripted to add mutagenic oligos to
plasmid constructs with inserts, wherein the Quik-
Change® site directed mutagenesis method is then used
to obtain the desired mutated constructs [12].
Gene Composer supports recombinational cloning (ie.
Gateway
®), restriction enzyme (RE) cloning, ligase
independent cloning (LIC) [13], and polymerase incom-
plete primer extension (PIPE) cloning [14]. For Gate-
way® cloning, Gene Composer designs terminal
amplimers (forward and reverse) with the required
recombination sequences recognized by recombinase
enzyme to affect recombination with the vector DNA to
form the final constructs. For restriction enzyme cloning,
Gene Composer allows the user to create custom
terminal amplimers with defined terminal restriction
enzyme recognition sites and any extra bases needed to
ensure efficient restriction enzyme cutting at ends. For
LIC and PIPE methods, Gene Composer allows the user
to define standard terminal amplimers with the neces-
sary terminal LIC or PIPE cloning sequences.
The Gateway
®, RE, and LIC methods for cloning each
require that the PCR insert samples be subjected to an
extra step of treatment or purification prior to mixing
with the vector sample for final cloning. In the case of
Gateway® cloning, the PCR products must be purified
away from amplimers that could otherwise interfere with
vector recombination. For RE cloning, the inserts must
be digested with restriction enzymes and then purified
away from the enzymes and terminal bits of DNA
released during digestion. For LIC cloning the inserts
must be purified away from nucleotides and primers, so
that they can be treated with T4 DNA polymerase to
affect a specific 3' to 5' single strand digestion of DNA
termini in the presence of a specific a defined deox-
ynucleotide triphosphate mix [13]. Each of these steps
adds extra time, cost, and complexity to the cloning
process. Moreover, in cases where the open reading
frame of the expressed target protein is produced as a
fusion protein encoded in part by sequences within the
vector, each of the Gateway
®,R E ,a n dL I Cp r o c e d u r e s
produces open reading frames with "extra" non-native
amino acids encoded by the terminal cloning sequences
used to adapt the insert to the vector.
In contrast, PIPE cloning enables the direct enzyme-free
cloning of PCR products without any unwanted "extra"
amino acid sequences in the final cloned open reading
frame. The PIPE method relies on the observation that a
significant quantity of PCR products have incompletely
polymerized strands, leaving single-stranded 5' over-
hangs of various length defined by the variable 3' end
points of the complementary strands [15]. Since the PCR
products all begin at 5'-ends that are defined by the
forward and reverse amplimers, both strands of a duplex
will together encompass the entire desired coding
sequence. With PIPE cloning, one set of primer pairs
are used to amplify the cloning vector in one PCR
reaction (vPCR), such that it is linearized with 5'
overhangs whose ends are complementary to 5' over-
hangs of insert PCR products (iPCR) which are generated
from a second pair of amplimers used to amplify the
insert DNA. Mixing the insert and vector PCR products
creates stably annealed fragments suitable for direct
c l o n i n gb yt r a n s f e c t i o ni n t ob a c t e r i aw h o s eD N A
replication and repair machineries effectively produce
the plasmids of interest. Virtually any PCR product can
be inserted into virtually any vector using this PIPE
approach, drastically reducing time and materials
required in a high throughput, cloning platform. Gene
Composer supports PIPE cloning by planning out all of
the required vPCR and iPCR reaction amplimers needed,
as well as the scripted pipetting steps to be executed by
the Tecan platform to complete the mixing of vPCR and
iPCR products so that they are ready for direct
transformation of bacteria (Figure 4).
Gene Design
The Gene Design Module uses a protein-to-DNA algorithm
to automate the "back-translation" of a protein amino acid
sequence into a codon engineered nucleic acid sequence.
This can be done for a variety of heterologous expression
systems based on their known codon bias represented in
pre-installed codon usage tables constructed from the
calculated codon frequencies from genomic sequence
information http://www.kazusa.or.jp/codon/[16]. In addi-
tion, the Gene Composer database contains modified
codon usage tables derived from codon preferences of
highly expressed proteins (HEXP-CUT), or hybrid codon
usage (HyCUT) designed to accommodate expression in
multiple systems, e.g., bacteria or insect cells. Users can also
generate their own preferred codon usage tables as more
genomic sequence data is published.
Page 7 of 22
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BMC Biotechnology 2009, 9:36 http://www.biomedcentral.com/1472-6750/9/36Figure 4
Amplimer planning for PIPE cloning. Gene Composer was used to plan the virtual and PIPE cloning of full-length and
terminal deletion constructs of a codon engineered Bacillus subtilis FtsZ gene. A, PIPE cloning is illustrated wherein the
synthetic gene insert (orange) is amplified by designed forward (red-orange lines) and reverse (orange-blue lines) primers to
generate insert PCR material (iPCR, ~900–1350 bp). The expression vector is amplified with reverse (red-black lines) and
forward (blue-black lines) primers to generate vector PCR material (vPCR, full length is ~5.8 Kbp). The terminal sequences
iPCR products are complementary to the terminal sequences of vPCR products (red of iPCR complements red of vPCR and
blue of iPCR complements blue of vPCR). This allows the iPCR and vPCR products to anneal to form circular DNA molecules
that are replicated upon transfection into host bacteria. B, Based on alignment analysis of the target amino acid sequence for
FtsZ to relevant PDB entries, terminal truncation points were selected (denoted by vertical bars in the base construct view).
Permutations of the terminal deletions were used to generate multiple constructs that were virtually cloned according to PIPE
parameters in Gene Composer (listed in the vector construct tab, below the base construct view). C, Agarose gel analysis of
PIPE Cloning constituents. After the terminal deletions of FtsZ-encoding constructs were designed and virtually cloned into
the expression vector. Gene Composer generated a spreadsheet file of all necessary amplification primers to produce iPCR
and vPCR products. This oligonucleotide file was uploaded directly to the oligonucleotides synthesis vendor website together
with information dictating the specific positions of the designed oligos in a 96-well plate. The, lyophilized oligos were
resuspended and used directly in an automated PIPE (polymerase incomplete primer extension) cloning procedure on a Tecan
EvoFreedom liquid handling robot. Agarose gel analysis of the iPCR in lanes 1–6, and vPCR in lane 7 products are shown
together with molecular size standards.
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(page number not for citation purposes)Prior to running the back-translation algorithm, users
are asked by Gene Composer to select a codon usage
table (CUT), define a minimal codon usage frequency
threshold to eliminate the use of "rare" codons and set
a target guanine:cytosine percentage (G:C%) content for
the intended expression system. Codons with fractional
usage above the minimal threshold setting are re-
normalized so that their fractional usage settings reflect
their relative proportional usage when rare codons are
eliminated. This allows the back-translation algorithm
to plan synthetic "codon engineered" gene sequences
that lack rare codons, but otherwise have codon usage
which mimics natural codon usage. This is achieved
algorithmically by random selection of available
codons in a weighted fashion according to their re-
normalized fractional usage. Based on these user
defined parameters, Gene Composer generates thou-
sands of possible new synonymous gene sequences for
any given protein sequence. The software then selects a
single synthetic gene sequence that most closely
matches the target G:C%.
If users wish to eliminate stable mRNA hairpins from
their synthetic gene sequences, the back-translation
algorithm can be run in "delta G" mode wherein the
standard back-translation is carried out together with a
user defined threshold for an allowable calculated
change in Gibbs free energy (ΔG) for local RNA folding.
In this mode, the standard back-translation algorithm
runs the Vienna RNA Package http://www.tbi.univie.ac.
at/RNA/ to calculate local RNA secondary structure and
minimum ΔG in a step-wise fashion across the entire
gene sequence [17]. The user is allowed to set the
window length of the local RNA (typically 50 bases),
step size (typically 10 bases) and salt concentration used
in the calculation. If the ΔG value for local RNA folding
violates a user-defined threshold for stable hairpin
formation, then the sequence is rejected and the back-
translation begins again. This feature helps to ensure that
synthetic codon engineered gene sequences will lack any
highly stable mRNA secondary structure such as a
hairpin or pseudoknot that could have a negative impact
on the fidelity of protein translation [18,19]. The default
setting is 100 iterations which the user may adjust to suit
his or her preferences. Additionally, the window size and
step size can be adjusted. The processing time for this
step will vary depending upon the user's equipment. A
3.0 GHz, Pentium 4 processor processed 100 iterations
of back-translation in the deltaG mode of p38a
(NP_620581, 360 amino acids, 1080 bp of DNA) in
approximately 45 sec. This step is only the first step of
our process. Detailed below are additional modifications
that the user may select to further enhance the gene
design and arrive at a highly optimized sequence. We
also want the reader to note that the user can elect to skip
the back-translation step and begin instead with a native
mRNA sequence. When modifying a native mRNA the
user still selects a codon usage table and codon
frequency cutoff. Within this framework, various engi-
neering tools (listed below) can be applied to modify a
native gene sequence. Moreover, the software allows
users to visualize graphically the location of rare codons
across a gene sequence relative to a selected codon usage
table and defined codon frequency threshold. This
allows the user to identify rare codons within native
gene sequences so that they may be appropriately
modified.
Synonymous Codon Engineering of Desired Sequence Features
Beyond simple back-translation, there are at least three
general classes of synonymous codon engineering features
that synthetic gene engineers may desire: (i) those that
facilitate DNA cloning operations such as the introduction
oreliminationofrestrictionenzymecleavagesites;(ii)those
that improve the "translation quality" of mRNA such as the
elimination of nucleotide repeats, codon repeats, cryptic
Shine-Dalgarnotranslationstart sites,ortheintroduction of
alternate reading frame "ambush" stop codons [20]; and
(iii) those that improve mRNA stability such as the
elimination of RNase cleavage sites or microRNA target
sequences [21]. Therefore, the Gene Design Module has
beenequippedwithseveraluniquecodonengineeringtools
that allow users to further modify the back-translated gene
sequence with silent/synonymous nucleotide changes to
introduce or eliminate nucleic acid sequence elements
(Figure 5). Manyof the design tool parameters canbe set by
the user to suit his or her specifications, however all of the
design tools have default settings which are used as guides.
All of the changes made by the user in later steps are made
within the context of the codon usage table and frequency
cutoff chosen at the beginning of the design process. When
applied to a gene sequence, each of the available codon
engineering strategies described below are tracked in the
Gene Composer database as a sequence of engineering
events. Inthisway,everystep ingeneengineeringistracked.
Additionally, the user is notified if a modification conflicts
with any previous modifications. The user is given the
option of accepting or rejecting the modification.
Silent Introduction or Removal of Restriction Endonuclease
Cleavage Sites
Many expression vector plasmids have multiple cloning sites
(MCS)withseveraluniquerestrictionenzymesequencesina
definedorderwhichfacilitatesunidirectionalcloningofgene
sequences. In order to take full advantage of the utility of
multiple cloning sites, careful synthetic gene design allows
one to use synonymous nucleotide changes to "silently"
eliminateundesiredMCSrestrictionendonucleasesitesfrom
the body of the open reading frame (Figure 6). In this way,
BMC Biotechnology 2009, 9:36 http://www.biomedcentral.com/1472-6750/9/36
Page 9 of 22
(page number not for citation purposes)the synthetic gene sequence can then be easily moved
between vectors with common MCS restriction sites.
The degeneracy of the genetic code, even when
constrained to the preferred codons of highly expressed
proteins, usually allows sufficient flexibility to enable
the "silent" introduction of unique restriction sites
located at strategic positions within the open reading
frame of the gene of interest. The introduction of
unique restriction sites throughout the body of a gene
e n a b l e si tt ob ec l e a v e di n t os e v e r a ld e f i n e dp i e c e s ,
which may be designed to encode alternate mutations
within each gene segment. In this way, re-ligation of the
pools of mutant gene segments allows for the rapid
generation of several combined mutations. This strategy
can be used to select for protein variants with desired
properties and can be a powerful combinatorial protein
engineering strategy. It should be noted that within the
within the restriction site database manager, users can
specify any DNA sequence, including wild card
sequences that they wish to consider for silent
introduction or removal without altering the amino
acid coding sequence.
Silent Removal of Cryptic Translation Initiation Sequences
When designing synthetic gene sequences for optimal
protein expression it is important to consider that simple
back-translation process may inadvertently design open
reading frame sequences with one or more cryptic Shine-
Dalgarno [22] or Kozak [23] translation initiation sites
i na n yo ft h et h r e ep o s s i b l er e a d i n gf r a m e s[ 2 4 ] .T h e
translation initiation signal for prokaryotic organisms
(bacteria), was identified by Shine and Dalgarno [22], as
ad e g e n e r a t ep u r i n er i c hs e q u e n c ew i t hag e n e r a l
consensus of 5'-UAAGGAGGU-3' located ~7 nucleotides
immediately upstream (on the 5' side) of a methionine
codon (AUG). Given the bipartite nature of the Shine-
Dalgarno initiator sequence and its relatively large size, it
is usually a simple task to for Gene Composer to identify
one or more synonymous single base changes that will
effectively eliminate the undesired "cryptic" Shine-
Dalgarno sequence within the constraints of previously
defined codon usage frequencies. The Gene Design
Module allows the user to choose one or more possible
silent changes that will eliminate "cryptic" Shine-
Dalgarno sequences.
In eukaryotic organisms, the Kozak consensus sequence
for translation initiation is loosely defined as 5'GCCAC-
CAUGG3' wherein translation initiation usually starts at
a methionine AUG codon within the sequence. Given
the relatively small size of the Kozak consensus
sequence, there are relatively few possible alternative
synonymous sequence choices that would eliminate an
unwanted cryptic Kozak site. As such, Gene Composer
Figure 5
Use of the degeneracy of the genetic code to silently alter DNA sequences without altering the amino acid
sequences. Synonymous codon changes can be categorized as (i) changes to improve DNA cloning features (left box, removal
of an EcoR1 site or introduction of a BamH1 site); (ii) changes to improve RNA quality for translation (middle box, removal of
a cryptic Shine-Dalgarno site, removal of base repeats, introduction of "ambush" out of frame stop codons, and removal of
mRNA hairpin); and (iii) changes to improve RNA stability (right box, removal of RNase or MazF cleavage sites). The DNA
encoding a target gene is shown as a solid black line, with sequences of interest in expanded view. Sequence elements with
underlined codon triplets which can be altered are shown above the line and the alternative synonymous sequences are shown
below the line.
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unwanted sequence of any size. The software will choose
any synonymous change that effectively eliminates the
defined sequence, even if its use would be counter to
previously defined codon usage parameters.
Silent Removal of Nucleic Acid and Codon Repeats
Sequence repeats of greater than five nucleotides in
length are a source of ribosomal frameshifting, wherein
the mRNA can "slip" out of frame [25]. Therefore, to
improve translation fidelity, nucleotide repeats in mRNA
should be silently eliminated by single base sequence
changes to effectively destroy their "slippery" nature.
Sequence repeats can be identified by the Gene Design
Module and removed by silent mutation. This is
achieved by simply replacing the first complete degen-
erate codon within any 5 base sequence repeat with an
alternative synonymous codon regardless of any pre-
viously defined codon usage constraints. Repeated use of
the same codon for a repeated amino acid (i.e. a hexa-
histidine) has been reported to have a negative effect on
translation kinetics and fidelity, likely due to depletion
Figure 6
Synonymous introduction and removal of DNA restriction enzyme sites. The Protein-to-DNA algorithm of Gene
Composer has generated a novel back-translated gene sequence, and has identified existing restriction sites that either can be
eliminated or introduced (listed above or below the nucleic acid sequence respectively) by synonymous mutation without
violating any user defined constraints on codon usage or G:C% content. Unique, single cutting restriction sites are shown in
green. The inset window shows a detailed list the location of each restriction site, its current sequence (from: column), and the
proposed alternate synonymous sequence (to: column) required to silently introduce/remove the restriction site.
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allows the user to identify any pair of duplicated
degenerate codons, and replace either the first or second
codon with an alternative synonymous codon.
Silent Introduction of Hidden "Ambush" Stop Codons in Alternate
Reading Frames
As noted above, the ribosomal machinery is not perfect
and can suffer a reading frame shift under certain
circumstances, such as when it encounters a stable RNA
hairpin, pseudoknot structure, or a "slippery" repeated
nucleotide sequence [18]. Once a frameshift occurs, the
resulting polypeptide will be synthesized with an out of
frame encoded C-terminus until a stop codon is reached.
In order to minimize the mis-translation distance
traveled by a frameshifted ribosome, it is desirable to
silently engineer hidden "ambush" stop codons into
both the -1 (second) and +1 (third) reading frames [20].
The presence of ambush stop codons scattered through-
out the gene helps to ensure that any frameshifted
ribosomes will reach a termination codon sooner rather
than later, thereby spending less overall time and energy
wasted on translation of defective proteins. The degen-
eracy of the genetic code is highly accommodative of a
wide range of frequencies of hidden stop codons, and
genomic open reading frames appear to have an over-
abundance of "ambush" codons compared to gene
sequences built solely on the basis of codon usage
frequencies, suggesting that the genetic code has evolved
to make use of "ambush" codons in some way (personal
observation). Gene Composer allows users to engineer
as many possible ambush codons as they may desire
within the previously defined constraints of codon
usage, G:C%, or local ΔG parameters. Generally, the
introduction of an ambush stop codon every ~100 base
p a i r si ss u f f i c i e n tt oh a l t2
nd or 3
rd frame translation and
thereby promote the termination of any mistranslated
proteins.
Silent Removal of Endoribonuclease Sites
Protein production levels from synthetic genes can
sometimes be improved by synonymous codon engi-
neering of mRNAs to resist destruction through the silent
elimination of RNase cleavage sites. This is handled by
Gene Composer using the same procedure described
above for the elimination of cryptic Kozak sequences.
Similarly, synonymous codon engineering by Gene
Composer can be used to create "ACA-less" mRNAs for
"single protein" production in strains of E. coli that carry
an inducible MazF gene. This gene encodes the MazF
endoribonuclease which cleaves any unstructured single-
stranded RNA molecules that contain the "ACA"
sequence [29]. Since most mRNA molecules naturally
contain at least one ACA sequence, the inducible
production of MazF in cells causes the destruction of
all mRNAs, except those that lack the "ACA" sequence.
With this approach, MazF is used to convert the E. coli
cells into a "quasi-dormant" state, lacking all mRNA
except for the mRNA encoded by the synthetic "ACA-
less" gene. The cells in this growth arrested state can be
concentrated and added to medium containing spin-
labeled organic salts, which results in the NMR-ready
labeling of only the protein of interest that is encoded by
the synthetic "ACA-less" gene. This MazF procedure for
producing only one protein of interest in vivo requires
that the gene of interest be engineered to silently
eliminate all "ACA" nucleotide combinations. Conveni-
ently, the degeneracy of the genetic code allows all
possible ACA coding sequences to be changed to
alternative synonymous coding sequences. Gene Com-
poser is capable of designing ACA-less genes through
synonymous codon engineering which eliminates the
ACA triplet in all three reading frames.
Synthetic Gene Production
Once a codon engineered gene sequence has been
formulated with the aid of the Gene Composer
protein-to-DNA algorithm, the gene can either be
purchased from a synthetic gene vendor, or be manu-
factured by PCR in a standard molecular biology lab
from the Oligo-sets designed by the Gene Composer
Gene Design Module. This module includes a gene-to-
oligonucleotide algorithm that is used to plan all
required overlapping oligonucleotides needed to synthe-
size a desired gene sequence by PCR [30-34], and for
physically cloning gene derivatives into selected vectors
by the most popular subcloning strategies including
ligase independent cloning (LIC), recombinational
cloning (ie. Gateway
®), traditional restriction enzyme
cloning, and the polymerase incomplete primer exten-
sion cloning method (PIPE) [14].
Oligo-set Creation
Gene Composer has the ability to design overlapping
oligonucleotide sets (Oligo-sets) for a variety of reported
PCR gene assembly methods that use a range of different
oligonucleotide building block sizes (Figure 7). As such,
the Oligo-set creation feature of the gene-to-oligo
algorithm requires five user defined oligonucleotide
parameters: i) a maximum oligo size, ii) a minimum
oligo size, iii) a target overlap size between any top and
bottom strand oligos, iv) the minimum Gibbs free
energy (ΔG) allowable for intramolecular oligonucleo-
tide folding, and iv) the salt concentration present in the
PCR reactions. The first three parameters are checked to
ensure that they do not conflict with the following rules.
The minimum must be less than the maximum, and the
minimum oligo size must be greater than or equal to
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and minimum oligo sizes must be greater than 5.
With these parameters defined, the gene-to-oligo algo-
rithm computationally cuts the top and bottom strand
sequences at random positions that are otherwise
constrained only by the aforementioned oligo size and
overlap constraints. The algorithm starts on the top
strand and generates the first cut by choosing a random
integer value between the maximum and minimum sizes
(inclusive). The algorithm continues marching down the
top strand in the 5' to 3' direction generating cuts until
the remaining length of the sequence is less than the
minimum oligo length. Once this point is reached, the
algorithm iteratively shifts all upstream cut sites by -1
base until the terminal oligo length is the size of the
target overlap length. This process adjusts the cuts across
the top strand such that the final ensemble of cuts
produces oligos that meet all of the user defined size
parameters. Once the top strand has been cut up, the
algorithm then generates bottom strand cuts by making
calculated cuts at nucleotide positions approximately
half way between the ends of the top strand oligos. This
ensures that each bottom strand cut falls in the
approximate middle of two top-strand oligos, which is
validated in a final step that checks that the top and
Figure 7
Oligo-set generation. The gene-to-oligonucleotide algorithm of Gene Composer has designed a set of overlapping
oligonucleotides (Oligo-set) which can be used in pooled PCR reactions to assemble the gene synthetically. The top window
shows all of the overlapping regions of oligonucleotides with annotation for the overlap Tm and overlap base length in
parentheses. The entire gene sequence is displayed in the lower panel.
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user defined parameters.
The gene-to-oligo algorithm is run thousands of times to
generate a large number of candidate Oligo-sets from
which to choose. The Oligo-sets are then ranked
according to their calculated average melting tempera-
ture (Tm) for the overlapping segments of each possible
top and bottom strand pair [35]. The ideal Oligo-set is
one that has the highest average Tm value and the lowest
overall variance in Tm, which together help ensure
fidelity in oligonucleotide pairing during pooled PCR
reactions for gene assembly. Moreover, an Oligo-set
should not contain any oligonucleotides that can form
stable hairpins (palindromic sequences), or which have
the same or similar sequence as other oligonucleotide
members. Therefore, the gene-to-oligo algorithm selects
only the best candidate Oligo-set which has the highest
average Tm,l o w e s tv a r i a n c ei nT m, and have a calculated
ΔG for intramolecular folding which is above the value
set during the backtranslation step [17].
Once the top candidate Oligo-set has been selected, the
gene-to-oligo algorithm proceeds to make further
improvements to the Oligo-set by adjusting the oligo-
nucleotide end points for any top and bottom strand
oligo pairs whose overlap Tm values are furthest from the
mean (both above and below). Once identified, the
algorithm determines how it can shift the oligonucleo-
tide endpoints to either raise the overlap Tm and/or bring
it closer to the mean. With each shift, a check is done to
ensure that the Oligo-set variables (minimum/maximum
size, overlap size) are not violated, and that the Tm is
closer to the mean and the overall Tm variance has been
reduced. The final Oligo-set is checked again to ensure
that no oligonucleotides violate the minimal allowable
ΔG for intramolecular folding.
Gene Synthesis by PCR Assembly in Combination With Base
Mismatch Surveillance
The Gene Composer protocol for PCR assembly (PCA)
of synthetic genes from designed oligonucleotides
(Oligo-sets) is illustrated in Figure 8 and is based on
an amalgam of the best practices in previously described
PCA methods [30-34]. PCA methods involving pools of
large numbers of oligonucleotides often fail to produce
the desired full-length gene product, which can usually
be attributed to the production of mis-primed PCR
products [33], which are more likely to form as the
variance in the Tm of overlaps between top and bottom
strands increases. The variance in overlap Tm is influ-
enced by both the number of oligos in the pool and their
average overlap length. Therefore, in order to improve
the successful outcome of gene synthesis, our Gene
Composer PCA protocol starts with the PCR production
of gene fragments from sub-pools of oligos. Once the
successful production of each overlapping gene fragment
has been confirmed by agarose gel electrophoresis or
capillary electrophoresis, all sub-gene fragments are
pooled for PCR amplification of the full length gene
using an excess of flanking primers covering the extreme
5' and 3' ends of the desired gene. While it is certainly
possible to obtain complete genes by PCA from a large
pool of oligos, we have found that the failure rate for
PCA from large pools is too high to justify this as a
standard approach to gene synthesis, and have therefore
adopted the sub-fragment/pool approach to PCA for
synthetic genes.
Most PCA-based gene synthesis methods can suffer from
a mutation rate of ~2 to 4 point mutations per 1–2K b p
of synthetic gene product [4,36-38]. The majority of
synthetic gene mutations are single nucleotide deletions,
and to a much lesser extent, base changes. The single
nucleotide deletions are the result of the presence of "N-
minus-1-mers" as contaminants in preparations of
synthetic oligonucleotides while the base changes are
usually attributable to polymerase mistakes that occur
during PCR assembly. N-minus-1-mers are oligonucleo-
tides that are missing one or more base(s) somewhere
within the sequence, which are the result of unavoidable
~<1.0% inefficiencies in each round of solid phase
oligonucleotide synthesis [4]. In order to eliminate base
deletions and mistakes in PCA-mediated gene synthesis,
researchers have taken advantage of the ability of
mismatch specific endonucleases to specifically recog-
nize and cleave both DNA strands at the site of base pair
mismatches in heteroduplex DNA. This editing proce-
dure involves the thermal denaturation and re-annealing
of full-length PCR gene products to produce hetero-
duplexes. During the denaturation and re-annealing
process, the chance that two strands of any given duplex
will re-anneal to each other is extremely low. As such,
only hetero-duplexes form upon re-annealing, wherein
they are comprised of strands that originated from two
different duplexes. Heteroduplexes that lack parity due
to a mistake in either the top or bottom strands will have
a base pair mismatch which can be recognized and
cleaved by a mismatch specific endonuclease. After
digestion of the mismatched heteroduplexes, the accu-
rately synthesized full-length DNA molecules can be
isolated away from the cleaved mutants by agarose gel
purification. Mismatch-specific endonucleases include
S1 nuclease, T4 endonuclease VII, T7 endonuclease I,
CEL 1 [30], and the MutHLS proteins. These enzymes
represent efficient tools for greatly improving the
accuracy of gene synthesis.
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PCA assembly of a gene from overlapping Oligo-sets. A, A schematic diagram of the PCR assembly of a synthetic gene
is shown (NS5B, HCV Polymerase). After design of the gene and creation of an Oligo-set using Gene Composer, the PCR gene
synthesis protocol is initiated by pooling overlapping complementary oligonucleotides which together comprise individual sub-
fragments (Pools 1–5) of the gene which are amplified by PCR and analyzed by agarose gel electrophoresis. B, PCR products of
sub-fragments from oligo Pools 1–5. Each product band is about 400 bp. C, The amplification products of Pool 1 (lane 1) are
denatured and re-annealed to generate heteroduplexes which are treated with CEL1 nuclease to digest any DNAs with base-
mismatches (lane 3, Pool 1 shows a smear of DNAs below ~400bp indicating that CEL1 was able to digest some of the
heteroduplexes, in comparison to lane 2 which is CEL1 treated Pool 1 that was not denatured and re-annealed and could
therefore not be digested with CEL1). D, The remaining CEL1 resistant intact (undigested) heteroduplex sub-fragments are gel
purified (Pools 1–5, lanes 1–5) and pooled for final assembly by PCR (lane 6, arrow). The expected size of the full length gene is
about 2,000 bp, and this material can be cloned directly into Topo activated vectors (Invitrogen).
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conjunction with PCA greatly reduces the error rate
synthetic gene production. Nevertheless, in order to
obtain a final sequence validated synthetic gene of ~1–2
Kbp, one may have to examine several (~5) independent
geneclonestoidentifyonewhichis100%accurate.Single
base mistakes can also be repaired by site-directed
mutagenesis, and/or by reconstructing the final gene
from sub-cloned gene fragments that are free of muta-
tions. Finally, many researchers may simply wish to
purchase afullysequencevalidated syntheticgeneoftheir
own design from a number of synthetic gene vendors.
Examples of PCA Gene Synthesis
We chose three genes as examples of our methods from
design to final synthetic gene product. These are the
human protein kinase P38a, the bacterial protein FtsZ
from Bacillus subtilis, and the Hepatitis C viral polymer-
ase NS5B. The sequences of these genes were re-designed
by codon engineering using Gene Composer as
described in the Materials and Methods. In Figure 8 we
demonstrate the stepwise results from each stage in the
synthetic gene production process by PCA with mis-
match specific endonuclease CEL1 error correction, using
the re-designed NS5B gene as an example. In addition to
constructing the re-designed genes, we also assembled
their native cDNA counterparts by PCA from overlapping
Oligo-sets planned by Gene Composer.
The sequence analysis results for several clone isolates of
the six synthetic genes (native cDNA and Gene Compo-
s e rd e s i g n sf o rP 3 8 a, FtsZ, and NS5B) are presented in
Table 1. The most common sequence error observed in
the products of PCA gene synthesis are single base
deletions which (despite the use of mismatch endonu-
clease error removal) most likely have their origins
rooted in the N-minus-1-mer problem with oligonucleo-
tide synthesis wherein despite high efficiency in oligo-
nucleotide synthesis there is a very small (but
nonetheless unavoidable) population of oligonucleo-
tides missing one base somewhere within their sequence.
However, even with the relative preponderance of single
base deletions, the statistics suggest that for genes less
than ~2 Kbp, choosing 4 clones to sequence will likely
yield at least one correct clone.
Discussion
Whole gene synthesis is rapidly becoming a powerful
and cost effective technology for creating novel proteins
and improving protein expression. To capitalize on the
availability of low cost synthetic genes, we have created a
database software package called Gene Composer™ that
facilitates the information-rich design of protein con-
structs and their nucleic acid coding sequences. This user
friendly software package enables the facile design of
totally novel nucleic acid sequences which are codon
engineered for improved protein production in hetero-
logous expression systems. We believe that computer
aided design software will allow researchers to efficiently
design protein constructs and synthetic genes which they
can order according to their own design (not just the
design provided by any given synthetic gene vendor).
The prospect of increasingly affordable synthetic genes
opens the opportunity to explore the effects of synon-
ymous gene sequence engineering for improved protein
production, or in some cases reduced protein production
[39]. Our efforts in building Gene Composer for
synthetic gene design are geared towards the develop-
ment of software that allows the user to have total
control over numerous gene design parameters and to
have the software be responsible for planning out all of
the required DNA (oligos, PCR products, vectors)
manipulations to be handled by liquid handling robots.
Gene Composer is not just a design tool but also an
informatics engine for manufacturing constructs. In this
way, researchers can spend more time designing
improved constructs, and less time having to think
about how to make the construct.
Table 1: Sequence errors for 6 synthesized genes
Gene Correct Clones Synonymous Changes Non-Synonymous Changes Deletions Other Mutations Totals
FtsZ 41 3 1 6 0 2 4
FtsZ/cDNA 21 2 1 4 5 2 4
NS5B 61 0 9 8 2 4
NS5B/cDNA 40 0 7 6 1 7
P38 92 4 6 0 2 1
P38/cDNA 81 0 3 0 1 2
Totals 33
(27%)
6
(5%)
9
(7%)
55
(45%)
19
(16%)
122
Multiple clones representing each of the 6 synthesized genes described in this manuscript were sequenced and the types or errors tabulated. On
average about 25% of the sequenced clones were correct. Errors resulting from base deletions were seen in about 50% of clones examined, most
likely the result of N-minus-1-mer problem with oligonucleotide synthesis wherein despite high efficiency in oligonucleotide synthesis there is a very
small amount but nonetheless unavoidable population of oligonucleotides missing one base somewhere within their sequence [4].
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dissemination of synthetic DNA technology to even very
small labs with modest investments in recombinant
DNA equipment (PC computer, thermal cycler, agarose
gel electrophoresis, UV illumination box, microcentri-
fuge, and temperature controlled environments). We
have shown that our PCA method for synthetic gene
assembly from Oligo-sets defined by Gene Composer
works reliably for both highly engineered synthetic gene
sequences and native cDNA sequences, with reasonably
low error rates of 1–2 mutations per 2 Kbp. Thus, Gene
Composer can aid even the smallest lab to produce
synthetic genes in any location where oligonucleotides
can be made or ordered for delivery.
Several companies now offer synthetic gene production
services (DNA 2.0, http://www.dna20.com; Codon
Devices, http://www.codondevices.com; Blue Heron,
http://www.blueheronbio.com; Geneart, http://www.
geneart.com; BioBasic, http://www.biobasic.com; Gen-
Script, http://www.genscript.com; Top Gene Technolo-
gies, http://www.topgenetech.com, and others) and
competitive technology development is expected to
continually drive prices lower. In general, most synthetic
gene production companies also offer limited gene
design services, for example to design genes with
preferred codons of a selected expression system.
However, we anticipate that the design parameters for
improved protein production through synonymous gene
sequence engineering of open reading frames will
ultimately require a more sophisticated user driven
approach. For this reason, we have intentionally enabled
Gene Composer to accept numerous user defined
settings for gene design parameters.
Conclusion
For structural biology applications, protein construct
engineering is guided by comparative sequence and
structural information, which allows the researcher to
better define domain boundaries for terminal deletions
and non-conserved regions for surface mutants. As such,
our efforts in developing Gene Composer software are to
integrate protein construct design together with synthetic
gene design where researchers are allowed flexibility to
design genes according to specific user-defined para-
meters. Table 2 offers an analysis of Gene Composer
features, relative to other available tools [38,40-43]. The
software allows users to design genes such that numer-
ous parameters can be held constant or varied. This
should allow users the opportunity to carryout com-
parative protein expression studies with designed genes
Table 2: Software and Website Applications for Designing Synthetic Genes
Name Database Codon
Engineering
Sequence
Engineering
Oligo-nucleotide
Engineering
Construct/Vector
Engineering
Protein
Engineering
Gene Composer ￿ CUT ￿ CWeighted Random ￿ Restriction Sites ￿ Gene Synthesis ￿ Yes ￿ Yes
￿ Genes ￿ G:C Content ￿ mRNA structure ￿ Mutagenesis
￿ Constructs ￿ Custom ￿ Repeat Removal
￿ Alignments ￿ A m b u s hS t o pC o d o n
￿ User defined Sequences
Optimizer ￿ CUT ￿ One Amino Acid –
one Codon
￿ No ￿ No ￿ No ￿ No
￿ Guided Random
￿ Custom
Gene Designer ￿ No ￿ One Amino Acid –
One Codon
￿ Restriction Sites ￿ No ￿ No ￿ No
￿ Random ￿ Repeat Removal
Gene Optimizer ￿ No ￿ Multiple parameter ￿ mRNA structure ￿ No ￿ No ￿ No
￿ Repeat Removal
￿ mRNA Splice Sites
DNA Works ￿ No ￿ Random ￿ Restriction Sites ￿ Gene Synthesis ￿ No ￿ No
Database refers to the presence or absence of a database to store codon usage tables (CUT), gene sequences (Genes), complete plasmid construct
sequences (Constructs), and alignments of protein sequences (Alignments). Codon Engineering refers to the methods used for back-translation of
amino acid sequences into nucleic acid sequences. Sequence Engineering refers to the ability to alter the nucleic acid sequence to introduce or
remove restriction sites, remove sequence repeats, alter potential mRNA secondary structures, remove mRNA splice sites or any other user defined
sequence. Oligonucleotide Engineering refers to the ability to design oligonucleotides to for gene synthesis or to create mutagenic primers.
Construct/Vector Engineering refers to the ability to visualize and create complete plasmid expression vectors using designed gene sequences.
Protein Engineering refers to the ability to create protein alignments to design specific protein constructs. Gene Composer: Emerald Biosystems,
http://www.genecomposer.net; Optimizer: Universitat Rovira i Virgili, genomes.urv.es/OPTIMIZER/; Gene Designer: DNA2.0, http://www.dna20.
com; Gene Optimizer: GeneArt, http://www.geneart.com; DNA Works: Helix Systems, http://helixweb.nih.gov/dnaworks/.
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be carefully measured. We do anticipate that such studies
may require hundreds of different experiments to
identify the value of any given design parameter for
improved protein production. Moreover, we anticipate
that the optimal design parameters may be specific for
certain protein families and expression systems. For
example, codon engineering may be used to alter
translation kinetics with respect to protein domain
organization, which in turn could modulate protein
function [40]. Thus, the burgeoning field of synthetic
biology has great promise to benefit from gene design
tools such as Gene Composer. In the sister manuscript to
this article [44] we demonstrate that the combination of
construct and codon engineering can have great utility
for improved heterologous protein production of infec-
tious disease targets for structural studies.
Methods
Reagents
Oligonucleotides were supplied by IDT (Coralville, IA)
as standard, desalted oligos and were used without
further purification. KOD polymerase was obtained from
Novagen (Madison, WI), and used for all PCR reactions
following the manufacturer's instructions. PCR frag-
ments were gel purified from agarose gels using a Qiagen
Gel Extraction Kit (Qiagen, Valencia, CA). Plasmid DNA
was prepared using a Qiagen Plasmid Purification Kit
(Qiagen, Valencia, CA). Restriction enzymes were
obtained from Fermentas (Hanover, MD) or New
England BioLabs (Ipswich, MA). T4 DNA ligase was
purchased from New England Biolabs. CEL1 nuclease
was purchased from Transgenomic, Inc (Omaha, NE).
Gene design and Gene Composer settings
Synthetic DNAs encoding FtsZ (Genbank code
NP_389412, amino acids 1–382), P38a (NP_620581,
amino acids 1–360) and Hepatitis C viral NS5B
(AAK08509, amino acids 2420–2898) were engineered
for expression in E. coli using Gene Composer software
(http://www.genecomposer.net, Emerald BioSystems,
Bainbridge Island, WA). Back-translation of the amino
acid sequence was accomplished using an E. coli highly
expressed protein codon usage table (Table 3). A
minimum threshold cut off for codon usage frequency
was set at 2%, eliminating codons with usage frequencies
less than 2%. Using these settings every amino acid,
except Met and Trp, have at least 2 codons available for
use.
Native cDNAs encoding these proteins were also
assembled (FtsZ, M22630, bp 1939–3084; P38a,
NM_139012, bp 339–1497; NS5B, AF333324, bp
7599–9371). No sequence optimization or alteration
was carried out for the cDNAs except to exclude certain
restriction enzyme sites from the body of the open
reading frame by synonymous codon engineering so as
to facilitate cloning into the expression vectors.
Synthetic genes were designed using the Gene Composer
protein-to-DNA back-translation algorithm using the
E.colihighlyexpressedproteincodonusagetabletogether
with the "ΔG" feature engaged to ensure that the resulting
mRNA sequence would not contain any highly stable
local mRNA folding elements. The minimal codon usage
cut off was set at 2% and the ΔG optimization was set to -
15 to -25 kcal/mol. In the ΔG mode, products of the back-
translation are interrogated for the presence of stable
Table 3: CodonusagefrequencytableforoptimalexpressioninE.coli.
AA Codon Freq AA Codon Freq
Ala GCA 0.28 Leu CTT 0.05
Ala GCC 0.07 Leu TTA 0.03
Ala GCG 0.21 Leu TTG 0.02
Ala GCT 0.45 Lys AAA 0.81
Arg AGA 0.02 Lys AAG 0.19
(Arg) AGG 0 Met ATG 1
(Arg) CGA 0 Phe TTC 0.79
Arg CGC 0.24 Phe TTT 0.21
(Arg) CGG 0.01 Pro CCA 0.08
Arg CGT 0.73 (Pro) CCC 0.01
Asn AAC 0.91 Pro CCG 0.82
Asn AAT 0.09 Pro CCT 0.08
Asp GAC 0.72 Ser AGC 0.15
Asp GAT 0.28 (Ser) AGT 0.01
Cys TGC 0.8 Ser TCA 0.02
Cys TGT 0.2 Ser TCC 0.39
Gln CAA 0.14 Ser TCG 0.04
Gln CAG 0.86 Ser TCT 0.39
Glu GAA 0.83 Stop TAA 0.83
Glu GAG 0.17 Stop TAG 0.17
(Gly) GGA 0 Stop TGA 0
Gly GGC 0.5 Thr ACA 0.02
(Gly) GGG 0.01 Thr ACC 0.56
Gly GGT 0.48 Thr ACG 0.05
His CAC 0.83 Thr ACT 0.36
His CAT 0.17 Trp TGG 1
Ile ATA 0.02 Tyr TAC 0.8
Ile ATC 0.86 Tyr TAT 0.2
Ile ATT 0.12 Val GTA 0.21
(Leu) CTA 0.01 Val GTC 0.07
Leu CTC 0.06 Val GTG 0.15
Leu CTG 0.83 Val GTT 0.57
Frequency refers to the percentage occurrence of synonymous codons
encoding amino acids in E. coli highly expressed proteins. The nucleic
acid sequences of the following genes were combined into a single
pseudo-gene and then used in the Kazusa Countcodon program http://
www.kazusa.or.jp/codon with eubacterial translation exceptions to
generate a codon usage table for that pseudo-gene: ompA (V00307),
atpE (V00266), cybB (AP009048), cybC (U14003), sdhC (AP009048),
groEL (AP009048), tufA (AP009048), rpsA (AP009048), rpsB
(NC_000913), rpoA (AP009048), rpoB (AP009048), rpoC (AP009048),
pheS (AP009048), pheT (AP009048), lysS (AP009048). Codons in
parentheses fall below the 2% frequency cutoff, and are not used during
back-translation when the threshold for codon usage is set at 2%.
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(page number not for citation purposes)mRNA hairpins in 50 bp windows. The process starts at
base pair 1 and examines the sequence from base pairs 1
to 50 then shifts 10 bp and interrogates again until the
entire length of the gene has been examined. Back
translated products with hairpins more stable than the
desired settings were rejected. Once a sequence meeting
the codon usage and ΔG cut-off was generated, other
sequence specific changes were made as follows. To
prevent the accumulation of mis-translated proteins
arising from ribosome slippage, improper translation
initiation or sequence errors, we introduced "ambush"
stop codons in the 2
nd and 3
rd reading frames approxi-
mately every 100 base pairs by substitution of synon-
ymous codons. For example, the sequence ACA AGA CAC
encoding the amino acid sequence Thr-Arg-Gln can be
changed to ACT AGA CAC, preserving the amino acid
sequence but introducing a stop codon (TAG) in the third
reading frame. Cryptic Shine-Dalgarno sequences
upstream from any AUG in all three reading frames
were also removed to prevent improper cryptic transla-
tion initiation. Restriction enzyme recognition sites for
BamHI and HindIII were also silently removed by
synonymous codon changes from both the synthetic
genes and native cDNAs to facilitate cloning.
The designed genes were then converted into Oligo-sets
using the Gene Composer gene-to-oligo algorithm. The
overlapping oligonucleotides on top and bottom strands
of the NS5B gene were optimized for overlapTm (65.84
to 87.84°C), ΔG of oligo folding (-1.50 to -17.80 kcal/
mol), and length (50–70 bases). The "Create Primers"
algorithm was used to organize the overlapping oligo-
nucleotides into pools of 5 or 6 with combined segment
lengths of 300–500 bp for each pool. The flanking
amplification primers were set to a Tm of 65°C to 80°C
and a length of 20 to 30 bases. Restriction sites were
added as 5' and 3' flanking sequences to the ends of the
primers in the primer design tool of Gene Composer.
The native gene sequences were divided into Oligo-sets
using the manual Oligo-set creation feature in Gene
Composer. The oligo size range was set to 50–70 bases
and the overlap to 23–40 bases. The specific Oligo-set used
was chosen from a calculated list of more than 100 possible
Oligo-setsandwas basedonhighminimum Tm and low Tm
variance for overlapping segments of the oligonucleotides.
TheautoimproveTmandimproveΔGfe at ur eswe reom it te d
from the Oligo-set optimization for cDNA samples to
prevent the introduction of synonymous changes. Primers
were generated in the same manner and with the same
parameters as for synthetic genes. The Oligo-sets for cDNA
gene synthesis were ordered from the same vendors and
assembled by PCA using the same methods as for the
synthetic codon engineered genes.
PCA gene synthesis
A two-stage PCR method is used to assemble synthetic
and cDNA coding sequences with an intervening mis-
match-dependent-endonuclease treatment of PCR pro-
ducts to reduce errors arising from PCR or from
oligonucleotides containing synthesis mistakes.
In Step 1, defined pools of overlapping oligonucleotides
and PCR primers (Oligo-sets) were used in individual
PCR reactions to produce individual gene sub-fragments
of 400–500 bp. Together, each of the gene sub-fragments
span the entire gene coding sequence, with overlaps
between sub-fragment ends of ~20–30 base pairs. Target
genes were parsed by Gene Composer into pools (Oligo-
sets) of 10–12 overlapping oligonucleotides (5–6o l i g o
pairs) for PCR amplification. Oligos in a solution
containing 2.8 mM Tris-HCl, pH 7.6, 0.4 mM KCl,
0.04 mM dithiothreitol, and 50 mM NaCl were mixed in
an equimolar ratio at a final concentration of 4 μMe a c h .
The mixture was then diluted 16-fold with water to
create a working stock for PCR, of which 2 μlo fe a c h
pool were individually amplified in a 50 μl PCR reaction
using KOD polymerase (2.5 Units) without amplifica-
tion primers in the manufacturer's buffer containing
0.12 M Tris-HCl, pH 8.0, 10 mM KCl, 6 mM (NH4)2SO4,
0.1% Triton X-100, 0.001% BSA. Four cycles of PCR were
performed at 94°C for 30 seconds, 72°C for 90 seconds,
and 72°C for 45 seconds. After 4 cycles, forward and
reverse amplification primers were added to a final
concentration of 200 nM each, and the reactions were
amplified for 26 cycles of 94°C for 30 seconds, 68°C for
90 seconds, and 72°C for 45 seconds, followed by a final
extension of 10 minutes at 72°C. Reaction products were
then separated on an agarose gel and the excised bands
of appropriate size were purified using a standard gel
extraction kit (Qiagen) into a volume of 50 μl of buffer
(10 mM Tris-HCl, pH 8.5).
In Step 2, the gel purified sub-fragments from Step 1
were heat denatured at 95°C for 10 minutes (20 μla t5 0
ng/μl), and then reannealed to form heteroduplexes by
decreasing the temperature of the solution at a rate of 0.1
degree per second for 10 minutes in a thermocycler in a
buffer containing 100 mM Tris-HCl, pH 8.0, 1 mM EDTA
and 1 M NaCl. The heteroduplexes were then treated
with the mis-match specific endonuclease CEL1 nuclease
(5 μl, Transgenomic, Inc.) in a 50 μl reaction at 40°C for
60 minutes (10 mM Tris-HCl, pH 8.8, 75 mM KCl, 1.5
mM MgSO4). The digested products were separated by
agarose gel electrophoresis and the "error-free" CEL1
resistant bands were purified using a standard gel
extraction kit (Qiagen) producing a final volume of 50
μl of purified CEL1 nuclease resistant sub-fragment in 10
mM Tris-HCl, pH8.5.
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(page number not for citation purposes)In Step 3, the full length coding sequences were
assembled using PCR by pooling 2 μl( ~ 1μg) of each
of the gel purified CEL1 resistant sub-fragments in a 50
μl reaction using KOD polymerase (2.5 Units) (Nova-
gen, Madison, WI) in the manufacturers buffer (0.12 M
Tris-HCl pH 8.0, 10 mM KCl, 6 mM (NH4)2SO4,0 . 1 %
Triton X-100, 0.001% BSA containing 200 nM of the
extreme 5' and 3'amplification primers (designed by
Gene Composer) containing the terminal restriction
enzyme recognition sites (BamHI and HindIII) or other
sequences necessary for final construct cloning. PCR was
performed for 26 cycles of 94°C for 30 seconds, 68°C
for 90 seconds, and 72°C for 45 seconds, followed by a
final extension of 10 minutes at 72°C. The final PCR
products were then gel purified (with or without prior
restriction enzyme digestion), and cloned into the
desired expression vectors. Alternatively, the final PCR
products can be subjected directly to LIC or PIPE cloning
methods.
Cloning
The concentration of gel purified synthetic genes from
PCA was determined by absorbance at 260 nm using a
NanoDrop ND-1000 spectrophotometer (Thermo Scien-
tific, Waltham, MA). DNA concentrations were adjusted
to 50 ng/μl or greater in 10 mM Tris-HCl, pH 8.5 and
then used for cloning into the pCR-Blunt II-TOPO vector
(Invitrogen) according to the manufacturer's instruc-
tions. One Shot™ TOP10 chemically competent E. coli
(Invitrogen) were transformed with 4.5 μlo ft h ec l o n i n g
reaction. Aliquots of 50 μl and 200 μlo ft r a n s f o r m e d
bacteria culture were spread on 2xYT agar plates contain-
ing 50 μg/ml kanamycin and incubated overnight at 37°
C. Single colonies of each of the constructs were grown
overnight in 2xYT media containing kanamycin (30 μg/
ml) and plasmid DNA was isolated by alkaline lysis
using the Qiagen plasmid purification kit according to
manufacturer specifications. Clones were sequenced with
vector primers M13F(-21) (5'-TGTAAAACGACGGC-
CAGT-3') and M13R(-29) (5'CAGGAAACAGCTAT-
GACC-3') by dideoxy termination using an Applied
B i o S y s t e m s ,I n c .( F o s t e rC i t y ,C A )3 7 3 0c a p i l l a r y
electrophoresis instrument. Sequence analysis was car-
ried out using Sequencher 4.7 DNA Sequence Analysis
Software (GeneCodes, Ann Arbor, MI). One correct clone
for each of the constructs was selected and digested from
the pCR-Blunt II-TOPO vector via double digest using
BamHI and HindIII restriction enzymes (Fermentas)
according to manufacturer specifications. Digested pro-
ducts were gel purified and the DNA was quantified by
absorbance at 260 nm using a NanoDrop ND-1000
spectrophotometer. A 3:1 molar ratio of the insert to
vector (15 ng/μl) is used to subclone into the final
expression vector using T4 DNA ligase (New England
Biolabs) following the manufacturer guidelines, but
increasing the suggested ligation time from 10 minutes
to 30 minutes in a 10 μlr e a c t i o na t2 2 ° Ci nb u f f e r
containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2,1 0
mM dithiothreitol, 1 mM ATP. One Shot TOP10
Chemically Competent E. coli (Invitrogen) are trans-
formed with 6 μl of the ligation reaction. Aliquots of 50
μl and 200 μl of transformed bacteria were spread on
2xYT plates containing 100 μg/ml ampicillin and
incubated overnight at 37°C. Resulting colonies were
s c r e e n e df o rp r o p e ri n s e r tu s i n gP C Ra n dv e c t o rs p e c i f i c
primers and verified by DNA sequencing as described
above.
PIPE (Polymerase Incomplete Primer Extension) Cloning
The gene of interest is amplified in the insert PCR
reaction (iPCR) with chimeric primers, with homology
to both the gene terminus and the vector junction (see
Figure 4 for details). The entirety of the expression vector
into which the gene will be cloned is amplified in the
vector PCR reaction (vPCR), with primers that exclude
the ccdB negative selection cassette. PCR reactions are
performed using pfuTurbo (Invitrogen). The extension
time for the iPCR is 3 minutes, while the extension time
for the vPCR is adjusted to 14 min. to allow sufficient
time for amplification to occur. The vector for PIPE
cloning is a derivative of pET28a into which the coding
sequence of Smt3 has been cloned followed by a ccdB
cassette. Equal parts crude iPCR product and crude vPCR
product are combined and used to transform competent
cells.
Availability and requirements
Gene Composer™ software can be downloaded for free
from http://www.genecomposer.net by following a
simple click-through registration license. Operating
System: Windows® 2000/XP Hardware: Pentium® 4 or
Athlon® at 1 GHz with 1 GB RAM
Abbreviations
Oligo: Oligonucleotide; G:C%: guanine:cytosine percen-
tage content; PCR: Polymerase chain reaction; LIC: Ligase
independent cloning; PCA: PCR based gene assembly;
MCS: multiple cloning sites; CUT: codon usage table;
vPCR: PCR amplification of vector DNA for PIPE
cloning; PIPE: Polymerase incomplete primer extension;
iPCR: PCR amplification of insert DNA for PIPE cloning;
NMR: nuclear magnetic resonance.
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